TTY Biopharm (台灣東洋) reported a strong finish to 2025, with December net profit reaching NT$119 million (+25.4% MoM). For the full year, the company achieved record-breaking figures across revenue, net profit, and earnings per share.

• Financial Performance: Full-year revenue reached NT$6.453 billion (+9.48% YoY), with a net profit of NT$15.61 billion (+7.7% YoY) and an EPS of NT$6.28.
• Three-Pronged Strategy Success:
1. Complex Generics: Lipo-AB continues to perform well in the US, while a breast cancer targeted therapy has secured a Taiwan license and applied for entry into the Vietnam market.
2. In-Licensing: The hematology drug Minjuvi (licensed-in) officially entered the market last January, opening new therapeutic channels.
3. Domestic Innovation: The antibiotic Bobimixyn has successfully penetrated multiple hospital networks. TTY also expects to secure a new lung cancer targeted therapy license in Q4.

Resource: 東洋去年營收、獲利同創高，EPS 6.28元